These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

870 related articles for article (PubMed ID: 15031492)

  • 1. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis of Src tyrosine kinase inhibition with a new class of potent and selective trisubstituted purine-based compounds.
    Dalgarno D; Stehle T; Narula S; Schelling P; van Schravendijk MR; Adams S; Andrade L; Keats J; Ram M; Jin L; Grossman T; MacNeil I; Metcalf C; Shakespeare W; Wang Y; Keenan T; Sundaramoorthi R; Bohacek R; Weigele M; Sawyer T
    Chem Biol Drug Des; 2006 Jan; 67(1):46-57. PubMed ID: 16492148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl.
    Eck MJ; Manley PW
    Curr Opin Cell Biol; 2009 Apr; 21(2):288-95. PubMed ID: 19217274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protein kinase inhibitors as a therapeutic modality.
    Levitzki A
    Acc Chem Res; 2003 Jun; 36(6):462-9. PubMed ID: 12809533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel protein kinases and molecular mechanisms of autoinhibition.
    Cheetham GM
    Curr Opin Struct Biol; 2004 Dec; 14(6):700-5. PubMed ID: 15582394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design strategies for protein kinase inhibitors.
    Parang K; Sun G
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):617-29. PubMed ID: 15503864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural insights into the conformational selectivity of STI-571 and related kinase inhibitors.
    Mol CD; Fabbro D; Hosfield DJ
    Curr Opin Drug Discov Devel; 2004 Sep; 7(5):639-48. PubMed ID: 15503866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ErbB/HER receptor protein-tyrosine kinases and cancer.
    Roskoski R
    Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclin-dependent kinase inhibitors.
    Fischer PM; Endicott J; Meijer L
    Prog Cell Cycle Res; 2003; 5():235-48. PubMed ID: 14593718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting protein kinases in cancer therapy.
    Fabbro D; García-Echeverría C
    Curr Opin Drug Discov Devel; 2002 Sep; 5(5):701-12. PubMed ID: 12630290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of c-Met kinase domain complexes: a new specific catalytic site receptor model for defining binding modes of ATP-competitive ligands.
    Asses Y; Leroux V; Tairi-Kellou S; Dono R; Maina F; Maigret B
    Chem Biol Drug Des; 2009 Dec; 74(6):560-70. PubMed ID: 19909299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism-based design of a protein kinase inhibitor.
    Parang K; Till JH; Ablooglu AJ; Kohanski RA; Hubbard SR; Cole PA
    Nat Struct Biol; 2001 Jan; 8(1):37-41. PubMed ID: 11135668
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of protein kinase signaling pathways: emerging therapies for cardiovascular disease.
    Force T; Kuida K; Namchuk M; Parang K; Kyriakis JM
    Circulation; 2004 Mar; 109(10):1196-205. PubMed ID: 15023894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants.
    Breitenlechner CB; Friebe WG; Brunet E; Werner G; Graul K; Thomas U; Künkele KP; Schäfer W; Gassel M; Bossemeyer D; Huber R; Engh RA; Masjost B
    J Med Chem; 2005 Jan; 48(1):163-70. PubMed ID: 15634010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are MAP kinases drug targets? Yes, but difficult ones.
    Margutti S; Laufer SA
    ChemMedChem; 2007 Aug; 2(8):1116-40. PubMed ID: 17541990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.